Immune-activation as a therapeutic direction for patients with high-risk ovarian cancer based on gene expression signature (1)

ABSTRACT: The Japanese Serous Ovarian Cancer Study Group Advanced-stage ovarian cancer is one of the most lethal gynecologic malignancies. To improve prognosis of patients with ovarian cancers, a predictive biomarkers leading to personalized treatments are required. In this large-scale cross-platform study of six microarray datasets consisting of 1054 ovarian cancer patients, we developed a novel risk classification system based on a 126-gene expression signature for predicting overall survival by applying elastic net7 and 10-fold cross validation to a Japanese dataset A (n = 260). We further validated its predictive ability with the five other datasets using multivariate analysis. Also, through gene ontology and pathway analyses of 1109 high-risk ovarian cancer specific transcripts, we identified a

ORGANISM(S): Homo sapiens

SUBMITTER: Kosuke Yoshihara 

PROVIDER: E-GEOD-32062 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress